共查询到20条相似文献,搜索用时 31 毫秒
1.
Lam VW Spiro C Laurence JM Johnston E Hollands MJ Pleass HC Richardson AJ 《Annals of surgical oncology》2012,19(4):1292-1301
Background
Selected patients with unresectable colorectal liver metastases (CLM) may be rendered resectable after systemic chemotherapy. We reviewed the evidence of downsizing systemic chemotherapy followed by rescue liver surgery in patients with initially unresectable CLM. 相似文献2.
Sahin DA Agcaoglu O Chretien C Siperstein A Berber E 《Annals of surgical oncology》2012,19(3):850-855
Background
There are scant data in the literature about the use of PET in the management of patients undergoing RFA of colorectal liver metastases (CLM). The aim of this study is to look at the use of PET versus contrast-enhanced CT (ce CT) scans on the initial assessment and follow-up of patients with CLM undergoing laparoscopic RFA. 相似文献3.
Kulik U Framke T Grosshennig A Ceylan A Bektas H Klempnauer J Lehner F 《World journal of surgery》2011,35(9):2063-2072
Background
The percentage of elderly patients with colorectal liver metastases (CLM) has increased. Liver resection remains the only curative therapy; data evaluating the outcome in this age group is limited. Aim of the present study was to determine if postoperative morbidity, mortality, and other independent predictors influence survival in patients ≥70 years undergoing liver resection for CLM. 相似文献4.
Lalmahomed ZS Ayez N van der Pool AE Verheij J IJzermans JN Verhoef C 《World journal of surgery》2011,35(3):656-661
Background
The increased use of neoadjuvant chemotherapy and minimally invasive therapies for recurrence in patients with colorectal liver metastases (CLM) makes a surgical strategy to save as much liver volume as possible pivotal. In this study, we determined the difference in morbidity and mortality and the patterns of recurrence and survival in patients with CLM treated with anatomical (AR) and nonanatomical liver resection (NAR). 相似文献5.
Introduction
Only 15% of patients with colorectal liver metastases (CLM) are candidates for curative hepatectomy at time of diagnosis, limited by anatomical location and tumor burden. Ablative therapies may extend this. This study reports a single institution’s long-term experience with hepatic cryotherapy for advanced CLM. 相似文献6.
Eddie K. Abdalla 《Journal of gastrointestinal surgery》2011,15(3):416-419
Introduction
The gold-standard treatment for colorectal liver metastases (CLM) is liver resection. Advances in staging, surgical technique, perioperative care and systemic chemotherapy have contributed to steady improvement in oncologic outcomes for patients following surgery in this subset of patients with stage IV colorectal cancer. The limits of resection continue to expand to include patients with more, larger and bilateral CLM, yet outcomes continue to improve with 5-year overall survival exceeding 50% following resection. Chemotherapy is an important element of treatment for patients with CLM, and chemotherapy can be combined safely with surgery to improve outcomes further. 相似文献7.
Patrick Pessaux Ettore Marzano Selenia Casnedi Philippe Bachellier Daniel Jaeck Marie-Pierre Chenard 《World journal of surgery》2010,34(11):2765-2772
Background
The aim of this study was to analyze the effects of preoperative cetuximab (cetu) on nontumorous liver parenchyma and the clinical and biological outcomes after liver resection for colorectal liver metastases (CLM). 相似文献8.
Narita M Oussoultzoglou E Chenard MP Fuchshuber P Rosso E Pessaux P Jaeck D Bachellier P 《Journal of gastrointestinal surgery》2012,16(3):554-561
Background
The adverse oncological effect of portal vein embolization (PVE) in patients with colorectal liver metastases (CLM) remains controversial. This study was designed to evaluate the effect of PVE on change of tumor characteristics using tumor specimens obtained from sequential hepatectomy before and after PVE. 相似文献9.
Purpose
The present study was performed to evaluate the depth of anal canal invasion (DACI), and determine whether magnetic resonance imaging (MRI) assessment of the conjoined longitudinal muscle (CLM) can be used to identify the surgical indication for intersphincteric resection. 相似文献10.
Guillaume?Passot Bruno?C.?Odisio Daria?Zorzi Armeen?Mahvash Sanjay?Gupta Michael?J.?Wallace Bradford?J.?Kim Suguru?Yamashita Claudius?Conrad Thomas?A.?Aloia Jean-Nicolas?Vauthey Yun?Shin?Chun
Background
The risk of colorectal liver metastases (CLM) disappearing on cross-sectional imaging has increased with advances in preoperative chemotherapy, but <50 % of disappearing CLM demonstrate complete pathological response.Objective
The aim of this study was to evaluate the role of fiducial marker placement before potentially curative treatment of CLM at risk of disappearing with chemotherapy.Methods
All consecutive patients who underwent fiducial placement for tracking of CLM at a tertiary center were reviewed.Results
Among 1377 patients undergoing CLM resection between 2005 and 2015, 35 patients underwent fiducial placement. Three patients were excluded due to disease progression. The study population comprised 32 patients who underwent fiducial placement in 41 CLM. Among the 41 marked CLM, 34 (83 %) were located >10 mm deep in the liver parenchyma, 25 (61 %) were in the right liver, and median size was 12 mm (range, 6–20 mm). No complication occurred after fiducial placement. After chemotherapy, 19 (46 %) of the 41 marked metastases disappeared on cross-sectional imaging. All fiducial-tracked CLM were treated with resection (n?=?31) or ablation (n?=?10). After median follow-up of 14 months (range, 0–64 months), no local recurrences were observed.Conclusion
Fiducial placement represents a safe procedure that facilitates accurate localization for resection or ablation of small CLM at risk of disappearing with chemotherapy.11.
Prins MJ Verhage RJ ten Kate FJ van Hillegersberg R 《Journal of gastrointestinal surgery》2012,16(5):956-966
Background
Cyclooxygenase isoenzyme-2 (COX-2) and vascular endothelial growth factor (VEGF) contribute to angiogenesis and are overexpressed in various malignancies. The aim of the study was to evaluate expression, prognostic value and correlation between COX-2 and VEGF expression in esophageal adenocarcinoma (EAC). 相似文献12.
Robbert J. de Haas Dennis A. Wicherts Eduardo Flores Michel Ducreux Francis Lévi Bernard Paule Daniel Azoulay Denis Castaing Antoinette Lemoine René Adam 《Annals of surgical oncology》2010,17(4):1010-1023
Background
As the real clinical significance of carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA19.9) evolution during preoperative chemotherapy for colorectal liver metastases (CLM) is still unknown, we explored the correlation between biological and radiological response to chemotherapy, and their comparative impact on outcome after hepatectomy. 相似文献13.
Pulitanò C Bodingbauer M Aldrighetti L Choti MA Castillo F Schulick RD Gruenberger T Pawlik TM 《Annals of surgical oncology》2012,19(2):435-442
Background
For patients with colorectal liver metastasis (CLM), the presence of concomitant perihepatic/para-aortic lymph node metastasis (LNM) is considered a contraindication to liver resection. We sought to determine the benefits of liver resection among patients with CLM + LNM by examining long-term outcomes among a large cohort of patients. 相似文献14.
Terence C. Chua Akshat Saxena Winston Liauw Adel Kokandi David L. Morris 《Annals of surgical oncology》2010,17(2):492-501
Background
Neoadjuvant chemotherapy prior to hepatectomy in patients with resectable colorectal liver metastases (CLM) may facilitate the resectability of the liver lesions and treat occult metastasis but may also lead to hepatic parenchyma damage. There is argument over the oncologic benefit of this practice in patients who would already be suitable for a curative hepatectomy. 相似文献15.
Purposes
Repeat hepatectomy remains the only curative treatment for recurrent colorectal liver metastasis (CLM) after primary hepatectomy. However, the repeat resection rate is still low, and there is insufficient data on the outcomes after repeat hepatectomy. The aim of this study was to investigate the feasibility and prognostic benefit of aggressive repeat hepatectomy for recurrent CLM.Methods
Data were reviewed from 282 consecutive patients who underwent primary curative hepatectomy for CLM between January 1994 and March 2015. The short- and long-term outcomes were analyzed.Results
One hundred ninety-three patients (68 %) developed recurrence, and repeat hepatectomy was conducted in 62 patients. Overall, 62 s, 11 third, 4 fourth, and 1 fifth hepatectomies were performed. The postoperative morbidity and mortality rates were low (11.5 and 1.3 %, respectively). The overall survival rates at 3 and 5 years after primary hepatectomy for CLM in the repeat hepatectomy group were 79.5 and 57.4 %, respectively. A multivariate analysis indicated that postoperative complications were independently associated with overall survival after repeat hepatectomy.Conclusions
Repeat hepatectomy for CLM is feasible, with acceptable rates of perioperative morbidity and mortality, and the potential for long-term survival. However, postoperative complications following aggressive repeat hepatectomy for CLM are associated with adverse oncological outcomes.16.
H. M. C. Shantha Kumara J. C. Cabot A. Hoffman M. Luchtefeld M. F. Kalady N. Hyman D. Feingold R. Baxter R. L. Whelan 《Surgical endoscopy》2010,24(2):283-289
Introduction
Plasma VEGF levels increase after minimally invasive colorectal resection (MICR) and remain elevated for 2–4 weeks. VEGF induces physiologic and pathologic angiogenesis by binding to endothelial cell (EC) bound VEGF-Receptor-1 (VEGFR1) and VEGFR2. Soluble forms of these receptors sequester plasma VEGF, decreasing the amount available to bind to EC-bound receptors. Ramifications of surgery-related plasma VEGF changes partially depend on plasma levels of sVEGFR1 and sVEGFR2. This study assessed perioperative sVEGFR1 and sVEGFR2 levels after MICR in patients with colorectal cancer. 相似文献17.
Luca Viganò Guido Costa Matteo Maria Cimino Fabio Procopio Matteo Donadon Daniele Del Fabbro Jacques Belghiti Norihiro Kokudo Masatoshi Makuuchi Jean-Nicolas Vauthey Guido Torzilli 《Journal of gastrointestinal surgery》2018,22(10):1752-1763
Background
A ≥?1-mm margin is standard for resection of colorectal liver metastases (CLM). However, R1 resection is not rare (10–30%), and chemotherapy could mitigate its impact. The possibility of detaching CLM from vessels (R1 vascular margin) has been described. A reappraisal of R1 resection is needed.Methods
A 19-question survey regarding R1 resection for CLM was sent to hepatobiliary surgeons worldwide. Seven clinical cases were included.Results
In total, 276 surgeons from 52 countries completed the survey. Ninety percent reported a negative impact of R1 resection (74% local recurrence, 31% hepatic recurrence, and 36% survival), but 50% considered it sometimes required for resectability. Ninety-one percent of responders suggested that the impact of R1 resection is modulated by the response to chemotherapy and/or CLM characteristics. Half considered the risk of R1 resection to be an indication for preoperative chemotherapy in patients who otherwise underwent upfront resection, and 40% modified the chemotherapy regimen when the tumor response did not guarantee R0 resection. Nevertheless, 80% scheduled R1 resection for multiple bilobar CLM that responded to chemotherapy. Forty-five percent considered the vascular margin equivalent to R0 resection. However, for lesions in contact with the right hepatic vein, right hepatectomy remained the standard. Detachment from the vein was rarely considered (10%), but 27% considered detachment in the presence of multiple bilobar CLM.Conclusions
A negative margin is still standard for CLM, but R1 resection is no longer just a technical error. R1 resection should be part of the modern multidisciplinary, aggressive approach to CLM.18.
Purpose
Investigate the expression of hepatocyte cell adhesion molecule (hepaCAM) and vascular endothelial growth factor (VEGF) mRNA in 55 cases of urothelial carcinoma to examine the potential relationship between hepaCAM and VEGF in urothelial carcinoma. 相似文献19.
Benckert C Thelen A Cramer T Weichert W Gaebelein G Gessner R Jonas S 《Surgery today》2012,42(2):169-176
Purpose
The roles of angiogenesis and the most prominent angiogenic vascular endothelial growth factor (VEGF) in diseases of the pancreas remain controversial. We compared microvessel density (MVD) and VEGF status in normal pancreatic, chronic pancreatic, and pancreatic cancer (PC) tissues to establish their prognostic relevance. 相似文献20.
Li-Jen Kuo Chin-Sheng Hung Wei-Yu Chen Yu-Jia Chang Po-Li Wei 《The Journal of surgical research》2013